Sickle cell disease (SCD) is a neglected genetic disease, especially in Africa, where an estimated 50% to 90% of patients die undiagnosed before their fifth birthdays.1 Globally, approximately 300,000 infants per year are born with homozygous SCD (HbSS).2 In Togo, a country of the West African region with approximately 7.889 million people, SCD is the most common hemoglobin (Hb) abnormality.3 The frequency of the HbS gene has been estimated at 16.1%, the prevalence of HbSS at 1.3%, and the prevalence of the double heterozygous forms (HbSC and HbS/β-thalassemia [βthal]) at 2.6%. Here, GSTM1 is linked to Schnyder corneal dystrophy.